Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + sulphonylurea
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Metformin + sulphonylurea is a combination therapy used to treat type 2 diabetes mellitus. It combines two different mechanisms of action to control blood glucose levels. Metformin (a biguanide) decreases glucose production in the liver, slows intestinal absorption of glucose, and improves insulin sensitivity. Sulphonylureas (such as glipizide or glyburide) stimulate the pancreas to release more insulin. This combination is typically prescribed when diet, exercise, and monotherapy with either agent alone fail to achieve adequate glycemic control.
- Brand names
- GlucovanceMetaglip
- Other names
- glipizide/metforminglyburide/metformin
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)OCT1 (Organic cation transporter 1)SUR1 (Sulfonylurea receptor 1)
Beyond the preview
Go deeper on metformin + sulphonylurea.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + sulphonylurea.